Tempest Therapeutics (TPST)
(Delayed Data from NSDQ)
$7.49 USD
+0.26 (3.60%)
Updated Aug 1, 2025 04:00 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TPST 7.49 +0.26(3.60%)
Will TPST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TPST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TPST
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up
TPST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TPST
Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial
Tempest Therapeutics Secures $4.1M in Direct Offering
Tempest Therapeutics (TPST) Announces New Stock Purchase Agreement | TPST Stock News
Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%
Tempest prices 739,000 shares at $6.25 in registered direct offering